Generally, addressing patients with breast cancer and visceral crisis remains a challenge, usually because chemotherapy is often not an option due to liver dysfunction and because the effectiveness of existing anti-HER2-targeted therapies has not been evaluated in randomized trials. Here, ERBB2 is linked to breast carcinoma.